Aliases & Classifications for Prostatitis

MalaCards integrated aliases for Prostatitis:

Name: Prostatitis 12 75 55 44 15 17 72

Classifications:



External Ids:

Disease Ontology 12 DOID:14654
ICD9CM 35 601 601.9
MeSH 44 D011472
NCIt 50 C26866
SNOMED-CT 68 9713002
ICD10 33 N41 N41.9
UMLS 72 C0033581

Summaries for Prostatitis

MalaCards based summary : Prostatitis is related to prostate disease and prostate sarcoma, and has symptoms including prostatism An important gene associated with Prostatitis is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Saw palmetto and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 75 Prostatitis is inflammation of the prostate gland. Prostatitis is classified into acute, chronic,... more...

Related Diseases for Prostatitis

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1990)
# Related Disease Score Top Affiliating Genes
1 prostate disease 34.8 NKX3-1 MSMB KLK3
2 prostate sarcoma 34.8 NKX3-1 KLK3
3 prostate cancer 34.1 VDR TGFB1 PROS1 NKX3-1 MSMB KLK3
4 acute cystitis 31.6 KLK3 IL6 CXCL8
5 nephrogenic adenoma 31.1 NKX3-1 KLK3
6 cystitis 31.0 TNF IL6 CXCL8
7 end stage renal failure 30.6 TNF TGFB1 IL6
8 exanthem 30.6 TNF IL6 IL2
9 purpura 30.3 TNF PROS1 IL6
10 cardiogenic shock 30.3 TNF IL6
11 pulmonary tuberculosis 30.3 VDR TNF IL2 IL10
12 submandibular gland disease 30.2 TGFB1 KLK3
13 osteoarthritis 30.2 TNF TGFB1 IL6 IL1B
14 spinal cord injury 30.2 TNF TGFB1 IL6 CXCL8
15 breast disease 30.2 TNF TGFB1 KLK3
16 alpha-2-macroglobulin deficiency 30.1 PROS1 KLK3
17 mycobacterium tuberculosis 1 30.1 VDR TNF IL10
18 male reproductive organ cancer 30.1 NKX3-1 MSMB KLK3
19 bone disease 30.0 VDR TNF IL6 IL1B
20 melioidosis 29.9 TNF IL6 IL10
21 trichomoniasis 29.9 IL2 CXCL8
22 posterior urethral valves 29.9 TNF TGFB1 IL6
23 obstructive jaundice 29.8 TNF IL6 CXCL8
24 myeloma, multiple 29.8 TNF IL6 IL2 CXCL8
25 fasciitis 29.8 TNF IL6 CXCL8
26 acute pyelonephritis 29.8 IL6 IL10 CXCL8
27 localized scleroderma 29.7 TNF TGFB1 IL6
28 pouchitis 29.7 IL10 CXCL8
29 schistosomiasis 29.7 TNF IL2 IL10
30 pulmonary disease, chronic obstructive 29.7 TNF TGFB1 IL6 CXCL8
31 periodontitis, chronic 29.6 IL6 IL1B
32 oral tuberculosis 29.6 TNF IL2
33 acute pancreatitis 29.6 IL6 IL10 CXCL8
34 adult dermatomyositis 29.6 VDR TNF
35 connective tissue disease 29.6 TNF IL6 IL10
36 echinococcosis 29.5 TNF IL6 IL10
37 osteoporosis 29.5 VDR TNF TGFB1 IL6 IL1B
38 necrotizing fasciitis 29.5 IL6 IL2 CXCL8
39 arteries, anomalies of 29.5 TNF IL6 IL1B
40 conjunctivitis 29.4 IL6 IL2 CXCL8
41 endometriosis 29.4 IL6 IL1B CXCL8
42 sarcoidosis 1 29.4 TNF IL2 IL1B
43 myasthenia gravis 29.4 TNF IL2 IL10
44 endocarditis 29.3 TNF IL6 IL10 CXCL8
45 post-transplant lymphoproliferative disease 29.3 TNF IL6 IL10
46 pertussis 29.3 TNF IL6 IL1B IL10
47 vaginitis 29.2 IL6 IL1B CXCL8
48 bacterial sepsis 29.2 TNF IL10 CXCL8
49 human immunodeficiency virus type 1 29.2 TNF IL6 IL2 IL10
50 urinary system disease 29.2 TNF TGFB1 KLK3 IL6 IL2

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Epididymo-Orchitis Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatitis:



Diseases related to Prostatitis

Symptoms & Phenotypes for Prostatitis

UMLS symptoms related to Prostatitis:


prostatism

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ADRA1A CXCL8 IL10 IL1B IL2 TGFB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ADRA1A CXCL8 IL10 IL1B IL2 TGFB1

MGI Mouse Phenotypes related to Prostatitis:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 ADRA1A IL10 IL1B IL2 IL6 PROS1
2 homeostasis/metabolism MP:0005376 10.13 ADRA1A IL10 IL1B IL2 IL6 NKX3-1
3 endocrine/exocrine gland MP:0005379 10.08 IL10 IL2 IL6 MSMB NKX3-1 TGFB1
4 hematopoietic system MP:0005397 10.06 IL10 IL1B IL2 IL6 PROS1 TGFB1
5 digestive/alimentary MP:0005381 10.04 IL10 IL2 IL6 NKX3-1 TGFB1 TNF
6 mortality/aging MP:0010768 10.02 ADRA1A IL10 IL1B IL2 IL6 NKX3-1
7 integument MP:0010771 9.95 IL10 IL1B IL6 PROS1 TGFB1 TNF
8 liver/biliary system MP:0005370 9.85 IL10 IL2 IL6 PROS1 TGFB1 TNF
9 muscle MP:0005369 9.8 ADRA1A IL10 IL6 PROS1 TGFB1 TNF
10 neoplasm MP:0002006 9.76 IL10 IL1B IL2 IL6 MSMB NKX3-1
11 reproductive system MP:0005389 9.56 IL10 IL2 IL6 MSMB NKX3-1 TGFB1
12 skeleton MP:0005390 9.17 IL10 IL1B IL6 NKX3-1 TGFB1 TNF

Drugs & Therapeutics for Prostatitis

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Saw palmetto Approved, Experimental, Investigational Phase 4
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Methyltestosterone Approved Phase 4 58-18-4 6010
4
Testosterone enanthate Approved Phase 4 315-37-7 9416
5
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
6
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
7
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
10
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
11
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
12
BCG vaccine Investigational Phase 4
13 Saw palmetto extract Phase 4
14 Acidophilus Phase 4
15 Anabolic Agents Phase 4
16 Testosterone 17 beta-cypionate Phase 4
17 Anesthetics Phase 4
18 Immunologic Factors Phase 4
19 Adjuvants, Immunologic Phase 4
20 Vaccines Phase 4
21 Alkylating Agents Phase 4
22 Mitomycins Phase 4
23 Neurotransmitter Agents Phase 4
24 Analgesics Phase 4
25 Peripheral Nervous System Agents Phase 4
26 Neuromuscular Agents Phase 4
27 abobotulinumtoxinA Phase 4
28 Cholinergic Agents Phase 4
29 Acetylcholine Release Inhibitors Phase 4
30 Botulinum Toxins Phase 4
31 Botulinum Toxins, Type A Phase 4
32 Central Nervous System Depressants Phase 4
33 Tranquilizing Agents Phase 4
34 Psychotropic Drugs Phase 4
35 Anti-Anxiety Agents Phase 4
36 Anticonvulsants Phase 4
37 Sildenafil Citrate Phase 4 171599-83-0
38 Citrate Phase 4
39 Phosphodiesterase Inhibitors Phase 4
40 Phosphodiesterase 5 Inhibitors Phase 4
41 Vasodilator Agents Phase 4
42 Antimanic Agents Phase 4
43 Excitatory Amino Acid Antagonists Phase 4
44 Excitatory Amino Acids Phase 4
45 Gastrointestinal Agents Phase 4
46 Cathartics Phase 4
47 Carboxymethylcellulose Sodium Phase 4
48 Antiparasitic Agents Phase 4
49 Laxatives Phase 4
50 Antimalarials Phase 4

Interventional clinical trials:

(show top 50) (show all 95)
# Name Status NCT ID Phase Drugs
1 Chronic Bacterial Prostatitis: Efficacy of Short-lasting Antibiotic Therapy With Prulifloxacin (Unidrox®) in Association With Saw Palmetto Extract, Lactobacillus Sporogens and Arbutin (Lactorepens®) Completed NCT02130713 Phase 4 Third generation fluoroquinolone
2 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
3 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
4 Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
5 Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention Completed NCT00422708 Phase 4
6 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
7 Effectiveness 0f Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Suspended NCT00194636 Phase 4
8 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
9 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
10 Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
11 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
12 A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
13 Randomized, Open-Labeled Study of Prophylactic Vs. Therapeutic Use of Uroxatrol to Determine Improvements in Urinary Morbidity Following Men Undergoing Prostate Brachytherapy Unknown status NCT00201630 Phase 3 Uroxatrol (drug)
14 A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis Completed NCT00236808 Phase 3 levofloxacin
15 A Double Blind, Sham Controlled Trial Evaluating the Efficacy of Acupuncture in Relieving Symptoms of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome Completed NCT00260637 Phase 2, Phase 3
16 Prospective, Multinational, Multicenter, Non-Comparative, Open Study With a 6 Months Follow-up Period to Demonstrate the Efficacy and Safety of Oral Levofloxacin 500 mg Once Daily in the Treatment of Chronic Bacterial Prostatitis (CBP) Completed NCT00277511 Phase 3 Levofloxacin
17 Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome Completed NCT00919893 Phase 3 Cernilton;Placebo
18 A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis Completed NCT00402688 Phase 3 levofloxacin;levofloxacin;levofloxacin
19 A Randomized Multicenter Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients Completed NCT00103402 Phase 3 Alfuzosin
20 A National, Multicentric, Randomised, Controlled Trial. Applications of a Critical Pathway Using Levofloxacin for the Management of Patients With Abnormal PSA. Completed NCT00169585 Phase 3 Levofloxacin oral tablets
21 Effects of Proxelan Somministration in Patients With Chronic Prostatitis Cat. IIa NIH: Pilot Study Recruiting NCT03629769 Phase 3 Proxelan
22 Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer: a Phase III Randomized Trial Recruiting NCT03862170 Phase 3 Ciprofloxacin;Cefazolin
23 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
24 A Multi-center Randomized Placebo Controlled Trial Evaluating the Efficacy of JALYN in Improving Symptoms in Men Diagnosed With Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
25 Prospective, Randomized, Open Label Phase 3 Study of the Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin for Treatment of Patients With Fluoroquinolone-susceptible Multidrugresistant-‐Tuberculosis (MDR-TB) Withdrawn NCT02975570 Phase 3 Delamanid;Linezolid;Levofloxacin;Pyrazinamide;WHO MDR-TB regimen
26 Prospective, Randomized, Partially Blinded, Phase 3 Study of the Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB Withdrawn NCT03828201 Phase 3 Delamanid;Levofloxacin;Bedaquiline;Clofazimine;Linezolid
27 Laparoscopic Prostatectomy for Chronic Prostatitis Unknown status NCT00775515 Phase 2
28 A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
29 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2 CC-10004
30 A Phase 2, 16 Week, Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel Group Proof-Of-Concept Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis Completed NCT00826514 Phase 2 Tanezumab;Placebo
31 A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of CP/CPPS Completed NCT01391338 Phase 2 ASP3652;Placebo
32 A Double-Blind, Randomized, Placebo-Controlled Trial of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Prostatitis Completed NCT00236990 Phase 2 pentosan polysulfate sodium
33 Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
34 Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma Completed NCT02017353 Phase 2
35 Pilot Study of Influence of Hyaluronic Acid (HA) on Bacillus Calmette-Guérin (BCG) Local Side Effects Completed NCT02207608 Phase 2 Hyaluronic Acid;BCG (Immucist®)
36 Phase II Placebo Controlled Trial of Preoperative Lycopene Supplementation in Prostate Cancer Patients Completed NCT00450749 Phase 2 lycopene
37 A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome Completed NCT00362752 Phase 2 Norfloxacin;Placebo
38 Evaluation of the Efficacy and Safety of Prulifloxacin vs Levofloxacin in the Treatment of Chronic Bacterial Prostatitis. Recruiting NCT03201796 Phase 2 Prulifloxacin 600 mg;Levofloxacin 500mg
39 Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
40 A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL) Recruiting NCT03576378 Phase 1, Phase 2 BrentuximabVedotin (BV)
41 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
42 A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Terminated NCT03500159 Phase 2 AQX-1125 200 mg;Placebo
43 A Prospective Pilot Study to Evaluate the Safety and Efficacy of Botox™ for the Treatment of Men Diagnosed With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Terminated NCT00529386 Phase 1 Botox
44 Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms Unknown status NCT00913315 tolterodine;tamsulosin;placebo
45 The Efficacy of Extracorporal Shock Wave Therapy on Symptoms Relief in Patients With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
46 Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A Double-Blind, Placebo-Controlled, Fixed-Dose,Randomized Controlled Study Unknown status NCT00656552 Early Phase 1 Escitalopram
47 A Single-Blinded Randomized Multi-Center Trial to Evaluate the Efficacy and Durability of Myofascial Tissue Manipulation in Women With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT00733603
48 Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT01843946
49 Non-interventional (Observational) Study of the Administration of Levolet® R, Film-coated Tablets (Dr. Reddy's Laboratories Ltd., India) in Adults With Chronic Prostatitis in Routine Clinical Practice Completed NCT02711943 Levofloxacin 500
50 Chemokine Mechanisms in Chronic Pelvic Pain Completed NCT01676857

Search NIH Clinical Center for Prostatitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cefazolin
Cephalexin
Ciprofloxacin
Flavoxate
Ofloxacin

Cochrane evidence based reviews: prostatitis

Genetic Tests for Prostatitis

Anatomical Context for Prostatitis

MalaCards organs/tissues related to Prostatitis:

41
Prostate, Testes, T Cells, Spinal Cord, Kidney, Brain, Bone

Publications for Prostatitis

Articles related to Prostatitis:

(show top 50) (show all 5551)
# Title Authors PMID Year
1
Association between periodontal disease and prostate-specific antigen levels in chronic prostatitis patients. 9 38
20450358 2010
2
[Clinical analysis of benign prostate hyperplasia with prostatitis]. 9 38
20448364 2010
3
Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. 9 38
20177031 2010
4
Crucial role of interferon-gamma in experimental autoimmune prostatitis. 9 38
20096883 2010
5
Antibacterial therapy improves the effectiveness of prostate cancer detection using prostate-specific antigen in patients with asymptomatic prostatitis. 9 38
19548108 2010
6
Is it possible to predict sepsis, the most serious complication in prostate biopsy? 9 38
20224265 2010
7
Prostate specific antigen, pelvic pain and prostatitis--time for a new paradigm? 9 38
19524944 2009
8
Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy. 9 38
19725275 2009
9
Management of elevated prostate-specific antigen in men with nonbacterial chronic prostatitis. 9 38
19570492 2009
10
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. 9 38
19603556 2009
11
Impact of vitamin D receptor activity on experimental autoimmune prostatitis. 9 38
19269787 2009
12
Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate. 9 38
18929399 2009
13
Incidence of histological prostatitis and its correlation with PSA density. 9 38
19936177 2009
14
Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). 9 38
19111800 2009
15
[Wardenafil in combined treatment of patients with chronic bacterial prostatitis]. 9 38
19256057 2008
16
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. 9 38
18668524 2008
17
Control of autoimmune diseases by the vitamin D endocrine system. 9 38
18594491 2008
18
Prevalence of delayed clinician response to elevated prostate-specific antigen values. 9 38
18380989 2008
19
The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. 9 38
18336465 2008
20
Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. 9 38
18362491 2008
21
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. 9 38
17637759 2008
22
Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. 9 38
18836536 2008
23
Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. 9 38
17695414 2007
24
Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). 9 38
17241782 2007
25
Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. 9 38
17300876 2007
26
Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. 9 38
17159365 2007
27
The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. 9 38
17111077 2007
28
Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions. 9 38
18595241 2007
29
Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. 9 38
17142748 2006
30
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. 9 38
16890703 2006
31
Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer. 9 38
16882055 2006
32
A sensitive proximity ligation assay for active PSA. 9 38
16800738 2006
33
Dealing with non-cancerous findings on prostate biopsy. 9 38
16630522 2006
34
Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies? 9 38
16401916 2006
35
Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. 9 38
17318358 2006
36
The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. 9 38
16385194 2006
37
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer. 9 38
16502048 2006
38
Pharmacological treatment for premature ejaculation. 9 38
16212722 2005
39
Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. 9 38
15993362 2005
40
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. 9 38
15947609 2005
41
[Asymptomatic prostatitis: a frequent cause of raising PSA]. 9 38
16209120 2005
42
Pure prostatic papillary adenocarcinoma with ductal features. 9 38
15852679 2005
43
The vicious cycling: bicycling related urogenital disorders. 9 38
15716187 2005
44
Ability of PSA-positive circulating macrophages to detect prostate cancer. 9 38
15389786 2005
45
PSA decrease after levofloxacin therapy in patients with histological prostatitis. 9 38
15693428 2004
46
Effect of NIH-IV prostatitis on free and free-to-total PSA. 9 38
15548444 2004
47
[Effect of inflammatory chronic pelvic pain syndrome on the levels of prostatic specific antigen]. 9 38
15638019 2004
48
Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer. 9 38
15636686 2004
49
Application of serum PSA to identify acute bacterial prostatitis in patients with fever of unknown origin or symptoms of acute pyelonephritis. 9 38
15264238 2004
50
Prostate carcinoma among men with human immunodeficiency virus infection. 9 38
15241826 2004

Variations for Prostatitis

Expression for Prostatitis

Search GEO for disease gene expression data for Prostatitis.

Pathways for Prostatitis

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 TNF TGFB1 IL6 IL2 IL1B IL10
2
Show member pathways
13.5 TNF TGFB1 IL6 IL2 IL1B IL10
3
Show member pathways
13.39 TNF TGFB1 IL6 IL2 IL1B IL10
4
Show member pathways
13.34 TNF TGFB1 IL6 IL2 IL1B IL10
5
Show member pathways
13.29 TNF TGFB1 IL6 IL2 IL1B IL10
6
Show member pathways
13.13 TNF TGFB1 IL6 IL2 IL1B IL10
7
Show member pathways
12.93 TNF TGFB1 IL6 IL1B CXCL8
8
Show member pathways
12.9 TNF TGFB1 IL6 IL2 IL1B IL10
9 12.86 TGFB1 NKX3-1 KLK3 IL6 IL2 CXCL8
10
Show member pathways
12.71 TNF TGFB1 IL6 IL2 IL1B
11
Show member pathways
12.64 TNF TGFB1 IL6 IL2 IL1B IL10
12
Show member pathways
12.6 TNF IL6 IL2 IL1B IL10
13
Show member pathways
12.6 TNF TGFB1 IL6 IL2 IL1B IL10
14 12.55 TNF IL2 IL1B IL10
15 12.36 TNF TGFB1 IL6 IL2
16
Show member pathways
12.34 TNF IL6 IL2 IL1B
17
Show member pathways
12.34 TNF IL6 IL1B CXCL8
18
Show member pathways
12.31 TNF IL6 IL1B CXCL8
19
Show member pathways
12.28 TNF TGFB1 IL1B IL10
20
Show member pathways
12.28 TNF IL6 IL2 IL1B IL10
21
Show member pathways
12.28 TNF TGFB1 IL6 IL2 IL1B IL10
22 12.27 VDR TNF TGFB1 IL6 IL1B IL10
23
Show member pathways
12.24 TNF IL6 IL1B CXCL8
24
Show member pathways
12.21 TNF IL6 IL1B CXCL8
25 12.16 TNF NKX3-1 IL6 IL1B IL10 CXCL8
26
Show member pathways
12.12 TGFB1 IL6 IL2 IL1B IL10 CXCL8
27
Show member pathways
12.09 TGFB1 KLK3 IL6
28
Show member pathways
12.06 TGFB1 IL6 IL10
29 12.04 TNF TGFB1 IL6
30 12.03 TNF IL6 IL2 IL10
31 12.02 TNF TGFB1 IL1B
32
Show member pathways
12.02 TNF IL6 IL1B
33
Show member pathways
12.02 TNF TGFB1 IL6 IL2 IL1B IL10
34 11.99 TGFB1 IL6 IL1B CXCL8
35 11.97 TNF TGFB1 IL6 IL1B CXCL8
36 11.96 TNF IL6 IL1B
37 11.96 TNF TGFB1 IL6 IL2 IL1B CXCL8
38 11.93 TNF TGFB1 IL6 IL1B CXCL8
39 11.91 TNF IL1B CXCL8
40 11.9 TNF TGFB1 IL6 IL1B IL10 CXCL8
41 11.89 TNF IL6 IL1B
42
Show member pathways
11.87 TGFB1 IL6 CXCL8
43 11.87 TGFB1 IL2 CXCL8
44 11.86 IL6 IL2 IL10
45 11.86 TNF IL2 IL1B IL10
46 11.84 TNF IL6 IL1B IL10 CXCL8
47 11.81 IL6 IL1B CXCL8
48 11.81 IL6 IL2 CXCL8
49 11.81 TNF TGFB1 IL6 IL1B IL10 CXCL8
50
Show member pathways
11.77 TNF IL2 CXCL8

GO Terms for Prostatitis

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNF TGFB1 PROS1 MSMB KLK3 IL6
2 secretory granule GO:0030141 9.33 TGFB1 KLK3 IL1B
3 extracellular space GO:0005615 9.32 TNF TGFB1 PROS1 MSMB KLK3 IL6

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.96 TNF TGFB1 IL2 IL1B
2 positive regulation of gene expression GO:0010628 9.95 VDR TNF TGFB1 NKX3-1 IL6 IL1B
3 leukocyte migration GO:0050900 9.94 TNF TGFB1 PROS1 IL1B
4 inflammatory response GO:0006954 9.91 TNF TGFB1 IL6 IL1B IL10 CXCL8
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF TGFB1 IL6 IL1B
6 response to drug GO:0042493 9.87 TGFB1 IL10 ADRA1A
7 response to organic substance GO:0010033 9.87 TNF TGFB1 IL10
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.86 TNF TGFB1 IL6
9 cellular response to organic cyclic compound GO:0071407 9.85 TNF TGFB1 IL1B
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 TNF TGFB1 ADRA1A
11 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 TNF IL6 IL1B IL10
12 positive regulation of protein phosphorylation GO:0001934 9.85 TNF TGFB1 NKX3-1 IL2 IL1B
13 positive regulation of T cell proliferation GO:0042102 9.83 IL6 IL2 IL1B
14 positive regulation of interleukin-6 production GO:0032755 9.83 TNF IL6 IL1B
15 negative regulation of fat cell differentiation GO:0045599 9.8 TNF TGFB1 IL6
16 positive regulation of cell division GO:0051781 9.79 TGFB1 NKX3-1 IL1B
17 positive regulation of interferon-gamma production GO:0032729 9.79 TNF IL2 IL1B
18 cellular response to lipopolysaccharide GO:0071222 9.77 TNF IL6 IL1B IL10 CXCL8
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.75 TNF TGFB1 IL1B
20 negative regulation of neurogenesis GO:0050768 9.73 TNF IL6 IL1B
21 positive regulation of chemokine production GO:0032722 9.72 TNF IL6
22 positive regulation of histone acetylation GO:0035066 9.72 TGFB1 IL1B
23 embryonic digestive tract development GO:0048566 9.72 TNF CXCL8
24 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.71 TNF IL1B
25 negative regulation of lipid catabolic process GO:0050995 9.71 TNF IL1B
26 regulation of regulatory T cell differentiation GO:0045589 9.71 TGFB1 IL2
27 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.71 TNF IL1B
28 negative regulation of growth of symbiont in host GO:0044130 9.71 TNF IL10
29 positive regulation of interleukin-17 production GO:0032740 9.7 TGFB1 IL2
30 response to molecule of bacterial origin GO:0002237 9.7 IL10 CXCL8
31 positive regulation of regulatory T cell differentiation GO:0045591 9.7 TGFB1 IL2
32 positive regulation of immunoglobulin secretion GO:0051024 9.7 IL6 IL2
33 positive regulation of glial cell proliferation GO:0060252 9.7 TNF IL6 IL1B
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 TNF IL1B IL10
35 negative regulation of lipid storage GO:0010888 9.68 TNF IL6
36 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IL1B
37 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
38 regulation of establishment of endothelial barrier GO:1903140 9.67 TNF IL1B
39 response to glucocorticoid GO:0051384 9.67 TNF IL6 IL10
40 negative regulation of cytokine secretion involved in immune response GO:0002740 9.66 TNF IL10
41 positive regulation of fever generation GO:0031622 9.65 TNF IL1B
42 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.64 TNF NKX3-1
43 sequestering of triglyceride GO:0030730 9.63 TNF IL1B
44 receptor biosynthetic process GO:0032800 9.61 TNF IL10
45 positive regulation of mononuclear cell migration GO:0071677 9.6 TNF TGFB1
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.59 TNF IL1B
47 protein kinase B signaling GO:0043491 9.56 TNF TGFB1 NKX3-1 IL1B
48 positive regulation of neuroinflammatory response GO:0150078 9.5 TNF IL6 IL1B
49 cytokine-mediated signaling pathway GO:0019221 9.5 TNF TGFB1 IL6 IL2 IL1B IL10
50 negative regulation of mitotic cell cycle GO:0045930 9.46 TNF TGFB1 NKX3-1 IL10

Molecular functions related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 TGFB1 IL6 IL2 IL10
2 cytokine activity GO:0005125 9.17 TNF TGFB1 IL6 IL2 IL1B IL10

Sources for Prostatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....